Back to Search Start Over

Pm-149 DOTA bombesin analogs for potential radiotherapy. in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2).

Authors :
Hu F
Cutler CS
Hoffman T
Sieckman G
Volkert WA
Jurisson SS
Source :
Nuclear medicine and biology [Nucl Med Biol] 2002 May; Vol. 29 (4), pp. 423-30.
Publication Year :
2002

Abstract

Promethium-149 (149Pm) is one of only three radiolanthanides that can be prepared in no carrier added concentrations. This high specific activity radiolanthanide is thus suitable for targeting limited numbers of specific receptors found on many tumor cells. Promethium-149 is a moderate energy beta(-) emitter (1.07 MeV (95.9%)) with a half-life of 2.21 days. Pm-149 also emits a low abundance of an imageable gamma ray (286 keV (3%)) that may allow in vivo tracking of the therapeutic dose. The 149Pm and Sm complexes with the DO3A-amide chelator with zero and three carbon spacers to the bombesin peptide analog BBN(7-14)NH(2) were synthesized and characterized. The Sm complexes were synthesized for macroscopic characterization purposes (ESI-MS, in vitro cell binding) since no stable isotopes of Pm are known. The biological properties of the 149Pm, 153Sm and 177Lu-DO3A-amide-betaAla-BBN complexes were compared in normal mouse biodistribution studies.

Details

Language :
English
ISSN :
0969-8051
Volume :
29
Issue :
4
Database :
MEDLINE
Journal :
Nuclear medicine and biology
Publication Type :
Academic Journal
Accession number :
12031877
Full Text :
https://doi.org/10.1016/s0969-8051(02)00290-1